Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update

About this update from Vivoryon Therapeutics N.v.

[{"type":"image","alt":"Vivoryon Therapeutics N.V.","displaySize":"","headline":null,"caption":"Vivoryon Therapeutics N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":96,"url":"https://media.zenfs.com/en/globenewswire.com/b42ca3f3b80b0385983aa04ad4cdc30c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/svDzxvBEhKQKFGa9AT1tMA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNA--/https://media.zenfs.com/en/globenewswire.com/b42ca3f3b80b0385983aa04ad4cdc30c","width":300,"height":96}},"lazy":false},{"type":"text","content":"Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update","length":102,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented at ERA 2025, ASN kidney week 2025 and at WCN 2026","length":154,"tagName":"p"}]},{"val":[{"type":"text","content":"Analysis of data for patients with lower baseline eGFR showed consistent and pronounced treatment effect in Phase 2 program, further supporting the Company’s plans to advance development in stage 3b/4 diabetic kidney disease (DKD) ","length":230,"tagName":"p"}]},{"val":[{"type":"text","content":"Novel composition of matter patent for varoglutamstat granted in the U.S.; patent term to provide exclusivity through 2044 with subsequent opportunity for patent term extension","length":176,"tagName":"p"}]},{"val":[{"type":"text","content":"Successful completion of private placement supported by existing and new shareholders raising EUR 5.1 million","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"Updated financial guidance: Vivoryon now expects cash and cash equivalents to be sufficient for funding operations into Q4 2026, providing financial runway and flexibility to realize strategic partnership","length":204,"tagName":"p"}]},{"val":[{"type":"text","content":"Management to host a conference call today at 3:00 pm CEST (9:00 am EDT)","length":72,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":945,"olType":false},{"type":"text","content":"Halle (Saale) / Munich, Germany, April 23, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary foc...

More updates from Vivoryon Therapeutics N.v.